# Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Study · id `cardio:ct-nct03969953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03969953](<https://clinicaltrials.gov/study/NCT03969953>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03969953

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1753 participants.

## Technical summary

Registry record NCT03969953. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-18 (actual); primary completion 2025-10-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1753 participants (enrolled count; ClinicalTrials.gov record NCT03969953, source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)
- Started: 2021-01-18 (actual) (ClinicalTrials.gov record NCT03969953, source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)
- Primary completion: 2025-10-30 (actual) (ClinicalTrials.gov record NCT03969953, source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)
- Completion: 2025-10-30 (actual) (ClinicalTrials.gov record NCT03969953, source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)
- Countries: Australia; Belgium; Canada; France; Germany; India; Malaysia; Nepal; Saudi Arabia; Singapore; Taiwan; Tunisia (ClinicalTrials.gov record NCT03969953, source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03969953-2026-03-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
- Acronym: TRACK
- Condition: Chronic Kidney Diseases
- Condition: Dialysis-dependent Kidney Failure
- Condition: Cardiovascular Disease
- Intervention (Drug): Rivaroxaban 2.5 Mg Oral Tablet
- Intervention (Other): Placebo
- Lead sponsor: The George Institute
- Lead sponsor class: OTHER
- Collaborator: Emerald Clinical Inc.
- Collaborator class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Central Hospital, Nancy, France
- Collaborator class: OTHER
- Collaborator: King Abdullah International Medical Research Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: The George Institute for Global Health (`core:george-institute`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Central Hospital, Nancy, France (`cardio:org-central-hospital-nancy-france`)
- Registry lists this organization as a collaborator: King Abdullah International Medical Research Center (`cardio:org-king-abdullah-international-medical-research-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial (`cardio:pubmed-42240165`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: efc765b15acbdb97f628bc54ef28a7443d91b13d601327fdfad17b25eed11178
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
